Is Wall Street Bullish or Bearish on DexCom Stock? Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects. Barchart · Aug 14
Earnings Preview: What To Expect From DexCom's Report DexCom is expected to announce its second-quarter earnings soon, and Wall Street expects the company’s EPS to increase by a double-digit percentage. Barchart · Jul 6
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound. MarketBeat · Jun 18
Is DexCom Stock Underperforming the Dow? DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook. Barchart · Jun 5
The DexCom Stock Turnaround Is Showing Real Signs of Life DexCom (DXCM) shares have put together an encouraging short-term bounce as the company maps out a multi-year growth algorithm. The stock currently carries a 8% “Sell” rating, but that’s up from the prior day’s 96% “Sell” rating and 100% “Sell” last week. A positive trend on that indicator. DXCM is... Barchart · May 20
Are Wall Street Analysts Bullish on DexCom’s Stock? Although DexCom has significantly underperformed the broader market over the past year, Wall Street analysts continue to maintain a very bullish outlook on the company’s long-term growth prospects. Barchart · May 15
3 Reasons Analysts Love DexCom Continuous glucose monitoring devices are vital to those with type 2 diabetes, and DexCom is cementing its position as a leader in this growing market. MarketBeat · May 5
DexCom’s Quarterly Earnings Preview: What You Need to Know DexCom is set to report its first-quarter results at month-end, and the Street is expecting a solid double-digit expansion in earnings. Barchart · Apr 19
Is DexCom Stock Underperforming the Nasdaq? DexCom has underperformed the Nasdaq Composite over the past year, yet analysts remain highly optimistic about the stock’s future. Barchart · Mar 5
What Are Wall Street Analysts' Target Price for DexCom Stock? Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects. Barchart · Feb 11
DexCom's Q4 2025 Earnings: What to Expect DexCom will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth. Barchart · Jan 15
Is DexCom Stock Underperforming the S&P 500? DexCom has considerably underperformed the S&P 500 over the past year, but analysts are highly optimistic about the stock’s prospects. Barchart · Dec 3, 2025
DexCom Stock: Is Wall Street Bullish or Bearish? Although DexCom stock has trailed the broader market over the past year, analysts remain bullish about its prospects. Barchart · Nov 13, 2025
Why TAL Education, Shake Shack And DexCom Just Appeared On Value Investors' Radars A trio of stocks made an impressive leap in their Benzinga Edge value scores this week, with one standout making a 138% jump. The three companies that have caught the eye of value investors are TAL Education Inc (NYSE:TAL), Shake Shack Inc (NYSE:SHAK) and DexCom Inc (NASDAQ:DXCM). Benzinga · Nov 8, 2025
Benzinga · Oct 28, 2025 DexCom Faces New Reports Of Deaths Linked To G7 Glucose Monitor DexCom Inc (NASDAQ:DXCM) is facing renewed scrutiny after three people with diabetes reportedly died following issues with its G7 continuous glucose monitor, according to adverse event filings submitted to the Food and Drug Administration in September.
Barchart · Oct 13, 2025 DexCom Earnings Preview: What to Expect DexCom is scheduled to announce its fiscal third-quarter earnings later this month, and analysts project a double-digit profit rise.
Benzinga · Sep 18, 2025 Short Report Alleges Dexcom Sold Faulty G7 Device Cited By FDA Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device.
MarketBeat · Sep 14, 2025 Best Bang For Your Buck? 2 Bargain Stocks with 30%+ Upside These two companies could present an opportunity for investors to gain access while they are relatively undervalued and before they appreciate once again.
Barchart · Sep 9, 2025 How Is DexCom's Performance Compared to Other Medical Device Companies? DexCom has outperformed the broader medical devices industry over the past year, and analysts remain strongly bullish on the stock’s prospects.
Kiplinger · Aug 28, 2025 DexCom, GE, SLB: Why Experts Rate These Stocks at Strong Buy Wall Street gives these three diverse names Strong Buy recommendations with high potential upside.
Barchart · Jul 7, 2025 What You Need to Know Ahead of DexCom’s Earnings Release DexCom is all geared up to announce its second-quarter earnings towards the end of this month, and analysts anticipate a single-digit bottom-line growth.
Barchart · Jul 1, 2025 2 ‘Strong Buy’ Stocks That the MAHA Movement AND Wall Street Love Policies associated with the MAHA movement could boost these two stocks significantly.
Barchart · Jun 16, 2025 DexCom Stock: Is DXCM Underperforming the Health Care Sector? DexCom has underperformed the Health Care sector over the past year, but analysts are highly optimistic about the stock’s prospects.
Barchart · Apr 11, 2025 What to Expect From DexCom's Next Quarterly Earnings Report DexCom will release its first-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.
Barchart · Mar 12, 2025 Is DexCom Stock Underperforming the Dow? DexCom significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s long term prospects.